Diaphragm adaptations in patients with COPD

Respiratory Research

Volumn 9, Issue , 2008, Pages

  Ottenheijm, Coen A C ^b   Heunks, Leo M A ^a   Dekhuijzen, Richard P N ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b University of Arizona   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADAPTATION; ANIMAL; ARTICLE; BIOLOGICAL MODEL; CHRONIC OBSTRUCTIVE LUNG DISEASE; DIAPHRAGM; HUMAN; MUSCLE ATROPHY; MUSCLE CONTRACTION; PATHOPHYSIOLOGY;

ADAPTATION, PHYSIOLOGICAL; ANIMALS; DIAPHRAGM; HUMANS; MODELS, BIOLOGICAL; MUSCLE CONTRACTION; MUSCULAR ATROPHY; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE;

EID: 40649108309     PISSN: 14659921     EISSN: 1465993X     Source Type: Journal    
DOI: 10.1186/1465-9921-9-12     Document Type: Review

References (115)

1. Lopez AD, Murray CC. The global burden of disease, 1990-2020. Nat Med 1998, 4:1241-1243. 10.1038/3218, 9809543.
2. Begin P, Grassino A. Inspiratory muscle dysfunction and chronic hypercapnia in chronic obstructive pulmonary disease. Am Rev Respir Dis 1991, 143:905-912.
3. Zielinski J, MacNee W, Wedzicha J, Ambrosino N, Braghiroli A, Dolensky J, Howard P, Gorzelak K, Lahdensuo A, Strom K, Tobiasz M, Weitzenblum E. Causes of death in patients with COPD and chronic respiratory failure. Monaldi Arch Chest Dis 1997, 52:43-47.
4. Gray-Donald K, Gibbons L, Shapiro SH, Macklem PT, Martin JG. Nutritional status and mortality in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1996, 153:961-966.
5. Newell SZ, McKenzie DK, Gandevia SC. Inspiratory and skeletal muscle strength and endurance and diaphragmatic activation in patients with chronic airflow limitation. Thorax 1989, 44:903-912.
6. Laghi F, Tobin MJ. Disorders of the respiratory muscles. Am J Respir Crit Care Med 2003, 168:10-48. 10.1164/rccm.2206020, 12826594.
7. Similowski T, Yan S, Gauthier AP, Macklem PT, Bellemare F. Contractile properties of the human diaphragm during chronic hyperinflation. N Engl J Med 1991, 325:917-923.
8. MacGowan NA, Evans KG, Road JD, Reid WD. Diaphragm injury in individuals with airflow obstruction. Am J Respir Crit Care Med 2001, 163:1654-1659.
9. Ottenheijm CA, Heunks LM, Dekhuijzen PN. Diaphragm muscle fiber dysfunction in chronic obstructive pulmonary disease: toward a pathophysiological concept. Am J Respir Crit Care Med 2007, 175:1233-1240. 10.1164/rccm.200701-020PP, 17413128.
10. Ottenheijm CA, Jenniskens GJ, Geraedts MC, Hafmans T, Heunks LM, Van Kuppevelt TH, Dekhuijzen PN. Diaphragm dysfunction in chronic obstructive pulmonary disease: a role for heparan sulphate?. Eur Respir J 2007, 30:80-89. 10.1183/09031936.00125106, 17392321.
11. Ottenheijm CAC, Heunks LMA, Li YP, Jin B, Minnaard R, van Hees HWH, Dekhuijzen PNR. Activation of ubiquitin-proteasome pathway in the diaphragm in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2006, 174:997-1002. 10.1164/rccm.200605-721OC, 16917114.
12. Moore AJ, Stubbings A, Swallow EB, Dusmet M, Goldstraw P, Porcher R, Moxham J, Polkey MI, Ferenczi MA. Passive properties of the diaphragm in COPD. J Appl Physiol 2006, 101:1400-1405. 10.1152/japplphysiol.01614.2005, 16840573.
13. Levine S, Gregory C, Nguyen T, Shrager J, Kaiser L, Rubinstein N, Dudley G. Bioenergetic adaptation of individual human diaphragmatic myofibers to severe COPD. J Appl Physiol 2002, 92:1205-1213.
14. Levine S, Nguyen T, Kaiser LR, Rubinstein NA, Maislin G, Gregory C, Rome LC, Dudley GA, Sieck GC, Shrager JB. Human diaphragm remodeling associated with chronic obstructive pulmonary disease: clinical implications. Am J Respir Crit Care Med 2003, 168:706-713. 10.1164/rccm.200209-1070OC, 12857719.
15. Levine S, Kaiser L, Leferovich J, Tikunov B. Cellular adaptations in the diaphragm in chronic obstructive pulmonary disease. N Engl J Med 1997, 337:1799-1806. 10.1056/NEJM199712183372503, 9400036.
16. Orozco-Levi M, Gea J, Lloreta JL, Felez M, Minguella J, Serrano S, Broquetas JM. Subcellular adaptation of the human diaphragm in chronic obstructive pulmonary disease. Eur Respir J 1999, 13:371-378. 10.1183/09031936.99.13237199, 10065684.
17. Barreiro E, de la PB, Minguella J, Corominas JM, Serrano S, Hussain SN, Gea J. Oxidative stress and respiratory muscle dysfunction in severe chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2005, 171:1116-1124. 10.1164/rccm.200407-887OC, 15735057.
18. Ottenheijm CAC, Heunks LMA, Sieck GC, Zhan WZ, Jansen SM, Degens H, de Boo T, Dekhuijzen PNR. Diaphragm Dysfunction in Chronic Obstructive Pulmonary Disease. Am J Respir Crit Care Med 2005, 172:200-205. 10.1164/rccm.200502-262OC, 15849324.
19. Doucet M, Debigare R, Joanisse DR, Cote C, Leblanc P, Gregoire J, Deslauriers J, Vaillancourt R, Maltais F. Adaptation of the diaphragm and the vastus lateralis in mild-to-moderate COPD. Eur Respir J 2004, 24:971-979. 10.1183/09031936.04.00020204, 15572541.
20. Orozco-Levi M, Lloreta J, Minguella J, Serrano S, Broquetas JM, Gea J. Injury of the Human Diaphragm Associated with Exertion and Chronic Obstructive Pulmonary Disease. Am J Respir Crit Care Med 2001, 164:1734-1739.
21. Ottenheijm CAC, Heunks LMA, Hafmans T, van der Ven PF, Benoist C, Zhou H, Labeit S, Granzier HL, Dekhuijzen PNR. Titin and Diaphragm Dysfunction in Chronic Obstructive Pulmonary Disease. Am J Respir Crit Care Med 2006, 173:527-534. 10.1164/rccm.200507-1056OC, 16339921.
22. Bellemare F, Cordeau MP, Couture J, Lafontaine E, Leblanc P, Passerini L. Effects of emphysema and lung volume reduction surgery on transdiaphragmatic pressure and diaphragm length. Chest 2002, 121:1898-1910. 10.1378/chest.121.6.1898, 12065355.
23. Polkey MI, Kyroussis D, Hamnegard CH, Mills GH, Green M, Moxham J. Diaphragm strength in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1996, 154:1310-1317.
24. Criner G, Cordova FC, Leyenson V, Roy B, Travaline J, Sudarshan S, O'Brien G, Kuzma AM, Furukawa S. Effect of lung volume reduction surgery on diaphragm strength. Am J Respir Crit Care Med 1998, 157:1578-1585.
25. Killian KJ, Jones NL. Respiratory muscles and dyspnea. Clin Chest Med 1988, 9:237-248.
26. Rochester DF, Braun NM. Determinants of maximal inspiratory pressure in chronic obstructive pulmonary disease. Am Rev Respir Dis 1985, 132:42-47.
27. Decramer M, de B, Dom R. Functional and histologic picture of steroid-induced myopathy in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1996, 153:1958-1964.
28. Polkey MI, Kyroussis D, Hamnegard CH, Mills GH, Hughes PD, Green M, Moxham J. Diaphragm performance during maximal voluntary ventilation in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1997, 155:642-648.
29. Mador MJ, Kufel TJ, Pineda LA, Sharma GK. Diaphragmatic fatigue and high-intensity exercise in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2000, 161:118-123.
30. Tobin MJ, Chadha TS, Jenouri G, Birch SJ, Gazeroglu HB, Sackner MA. Breathing patterns. 2. Diseased subjects. Chest 1983, 84:286-294. 10.1378/chest.84.3.286, 6884104.
31. Brooke MH, Kaiser KK. Muscle fiber types: how many and what kind?. Arch Neurol 1970, 23:369-379.
32. Peter JB, Barnard RJ, Edgerton VR, Gillespie CA, Stempel KE. Metabolic profiles of three fiber types of skeletal muscle in guinea pigs and rabbits. Biochemistry 1972, 11:2627-2633. 10.1021/bi00764a013, 4261555.
33. Schiaffino S, Gorza L, Sartore S, Saggin L, Ausoni S, Vianello M, Gundersen K, Lomo T. Three myosin heavy chain isoforms in type 2 skeletal muscle fibres. J Muscle Res Cell Motil 1989, 10:197-205. 10.1007/BF01739810, 2547831.
34. Bottinelli R, Reggiani C. Human skeletal muscle fibres: molecular and functional diversity. Prog Biophys Mol Biol 2000, 73:195-262. 10.1016/S0079-6107(00)00006-7, 10958931.
35. Mercadier JJ, Schwartz K, Schiaffino S, Wisnewsky C, Ausoni S, Heimburger M, Marrash R, Pariente R, Aubier M. Myosin heavy chain gene expression changes in the diaphragm of patients with chronic lung hyperinflation. Am J Physiol 1998, 274:L527-L534.
36. Mizuno M. Human respiratory muscles: fibre morphology and capillary supply. Eur Respir J 1991, 4:587-601.
37. Nguyen T, Shrager J, Kaiser L, Mei L, Daood M, Watchko J, Rubinstein N, Levine S. Developmental myosin heavy chains in the adult human diaphragm: coexpression patterns and effect of COPD. J Appl Physiol 2000, 88:1446-1456.
38. Ribera F, N'Guessan B, Zoll J, Fortin D, Serrurier B, Mettauer B, Bigard X, Ventura-Clapier R, Lampert E. Mitochondrial electron transport chain function is enhanced in inspiratory muscles of patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2003, 167:873-879. 10.1164/rccm.200206-519OC, 12493645.
39. Nguyen T, Rubinstein NA, Vijayasarathy C, Rome LC, Kaiser LR, Shrager JB, Levine S. Effect of chronic obstructive pulmonary disease on calcium pump ATPase expression in human diaphragm. J Appl Physiol 2005, 98:2004-2010. 10.1152/japplphysiol.00767.2004, 15718407.
40. Sauleda J, Gea J, Orozco-Levi M, Corominas J, Minguella J, Aguar C, Broquetas J, Agusti AG. Structure and function relationships of the respiratory muscles. Eur Respir J 1998, 11:906-911. 10.1183/09031936.98.11040906, 9623696.
41. Wijnhoven JH, Janssen AJ, Van Kuppevelt TH, Rodenburg RJ, Dekhuijzen PN. Metabolic capacity of the diaphragm in patients with COPD. Respir Med 2006, 100:1064-1071. 10.1016/j.rmed.2005.09.029, 16257195.
42. Sanchez J, Bastien C, Medrano G, Riquet M, Derenne JP. Metabolic enzymatic activities in the diaphragm of normal men and patients with moderate chronic obstructive pulmonary disease. Bull Eur Physiopathol Respir 1984, 20:535-540.
43. Horowits R, Kempner ES, Bisher ME, Podolsky RJ. A physiological role for titin and nebulin in skeletal muscle. Nature 1986, 323:160-164. 10.1038/323160a0, 3755803.
44. Tskhovrebova L, Trinick J. Titin: properties and family relationships. Nat Rev Mol Cell Biol 2003, 4:679-689. 10.1038/nrm1198, 14506471.
45. Granzier H, Labeit S. Cardiac titin: an adjustable multi-functional spring. J Physiol 2002, 541:335-342. 10.1113/jphysiol.2001.014381, 12042342.
46. Furst DO, Osborn M, Nave R, Weber K. The organization of titin filaments in the half-sarcomere revealed by monoclonal antibodies in immunoelectron microscopy: a map of ten nonrepetitive epitopes starting at the Z line extends close to the M line. J Cell Biol 1988, 106:1563-1572. 10.1083/jcb.106.5.1563, 2453516.
47. Sanchez J, Medrano G, Debesse B, Riquet M, Derenne JP. Muscle fibre types in costal and crural diaphragm in normal men and in patients with moderate chronic respiratory disease. Bull Eur Physiopathol Respir 1985, 21:351-356.
48. Scott A, Wang X, Road JD, Reid WD. Increased injury and intramuscular collagen of the diaphragm in COPD: autopsy observations. Eur Respir J 2006, 27:51-59. 10.1183/09031936.06.00143004, 16387935.
49. Engelen MP, Orozco-Levi M, Deutz NE, Barreiro E, Hernandez N, Wouters EF, Gea J, Schols AM. Glutathione and glutamate levels in the diaphragm of patients with chronic obstructive pulmonary disease. Eur Respir J 2004, 23:545-551. 10.1183/09031936.04.00022204, 15083752.
50. Jackman RW, Kandarian SC. The molecular basis of skeletal muscle atrophy. Am J Physiol Cell Physiol 2004, 287:C834-C843. 10.1152/ajpcell.00579.2003, 15355854.
51. Mitch WE, Goldberg AL. Mechanisms of muscle wasting. The role of the ubiquitin-proteasome pathway. N Engl J Med 1996, 335:1897-1905. 10.1056/NEJM199612193352507, 8948566.
52. McKinnell IW, Rudnicki MA. Molecular mechanisms of muscle atrophy. Cell 2004, 119:907-910. 10.1016/j.cell.2004.12.007, 15620349.
53. Glickman MH, Ciechanover A. The ubiquitin-proteasome proteolytic pathway: destruction for the sake of construction. Physiol Rev 2002, 82:373-428.
54. Ennen L, Heunks LM, van Hees HWH, Ottenheijm CAC, Dekhuijzen PNR. Effect of Bortezomib on Proteasome and Caspase-3 Activity in the Emphysematous Hamster Diaphragm. Am J Respir Crit Care Med 2007, 175:A502.
55. Du J, Wang X, Miereles C, Bailey JL, Debigare R, Zheng B, Price SR, Mitch WE. Activation of caspase-3 is an initial step triggering accelerated muscle proteolysis in catabolic conditions. J Clin Invest 2004, 113:115-123. 300763, 14702115, 10.1172/JCI200418330.
56. Lindahl U, Kusche-Gullberg M, Kjellen L. Regulated diversity of heparan sulfate. J Biol Chem 1998, 273:24979-24982. 10.1074/jbc.273.39.24979, 9737951.
57. Couchman JR. Syndecans: proteoglycan regulators of cell-surface microdomains?. Nat Rev Mol Cell Biol 2003, 4:926-937. 10.1038/nrm1257, 14685171.
58. Iozzo RV. Basement membrane proteoglycans: from cellar to ceiling. Nat Rev Mol Cell Biol 2005, 6:646-656. 10.1038/nrm1702, 16064139.
59. Jenniskens GJ, Veerkamp JH, Van Kuppevelt TH. Heparan sulfates in skeletal muscle development and physiology. J Cell Physiol 2006, 206:283-294. 10.1002/jcp.20450, 15991249.
60. Habuchi H, Suzuki S, Saito T, Tamura T, Harada T, Yoshida K, Kimata K. Structure of a heparan sulphate oligosaccharide that binds to basic fibroblast growth factor. Biochem J 1992, 285 ( Pt 3):805-813. 1132867, 1497618.
61. Turnbull JE, Fernig DG, Ke Y, Wilkinson MC, Gallagher JT. Identification of the basic fibroblast growth factor binding sequence in fibroblast heparan sulfate. J Biol Chem 1992, 267:10337-10341.
62. Lyon M, Deakin JA, Mizuno K, Nakamura T, Gallagher JT. Interaction of hepatocyte growth factor with heparan sulfate. Elucidation of the major heparan sulfate structural determinants. J Biol Chem 1994, 269:11216-11223.
63. Arai T, Parker A, Busby W, Clemmons DR. Heparin, heparan sulfate, and dermatan sulfate regulate formation of the insulin-like growth factor-I and insulin-like growth factor-binding protein complexes. J Biol Chem 1994, 269:20388-20393.
64. Feyzi E, Lustig F, Fager G, Spillmann D, Lindahl U, Salmivirta M. Characterization of heparin and heparan sulfate domains binding to the long splice variant of platelet-derived growth factor A chain. J Biol Chem 1997, 272:5518-5524. 10.1074/jbc.272.40.24850, 9038157.
65. McCaffrey TA, Falcone DJ, Du B. Transforming growth factor-beta 1 is a heparin-binding protein: identification of putative heparin-binding regions and isolation of heparins with varying affinity for TGF-beta 1. J Cell Physiol 1992, 152:430-440. 10.1002/jcp.1041520226, 1639873.
66. Bernfield M, Gotte M, Park PW, Reizes O, Fitzgerald ML, Lincecum J, Zako M. Functions of cell surface heparan sulfate proteoglycans. Annu Rev Biochem 1999, 68:729-777. 10.1146/annurev.biochem.68.1.729, 10872465.
67. Crisona NJ, Allen KD, Strohman RC. Muscle satellite cells from dystrophic (mdx) mice have elevated levels of heparan sulphate proteoglycan receptors for fibroblast growth factor. J Muscle Res Cell Motil 1998, 19:43-51. 10.1023/A:1005300426655, 9477376., http://
68. McFarland DC, Liu X, Velleman SG, Zeng C, Coy CS, Pesall JE. Variation in fibroblast growth factor response and heparan sulfate proteoglycan production in satellite cell populations. Comp Biochem Physiol C Toxicol Pharmacol 2003, 134:341-351. 10.1016/S1532-0456(02)00272-7, 12643981.
69. Casar JC, Cabello-Verrugio C, Olguin H, Aldunate R, Inestrosa NC, Brandan E. Heparan sulfate proteoglycans are increased during skeletal muscle regeneration: requirement of syndecan-3 for successful fiber formation. J Cell Sci 2004, 117:73-84. 10.1242/jcs.00828, 14627628.
70. Charge SB, Rudnicki MA. Cellular and molecular regulation of muscle regeneration. Physiol Rev 2004, 84:209-238. 10.1152/physrev.00019.2003, 14715915.
71. Alexopoulou C, Mitrouska I, Arvanitis D, Tzanakis N, Chalkiadakis G, Melissas J, Zervou M, Siafakas N. Vascular-specific growth factor mRNA levels in the human diaphragm. Respiration 2005, 72:636-641.
72. Kawai M, Brandt PW. Sinusoidal analysis: a high resolution method for correlating biochemical reactions with physiological processes in activated skeletal muscles of rabbit, frog and crayfish. J Muscle Res Cell Motil 1980, 1:279-303. 10.1007/BF00711932, 6971874.
73. Zhu E, Petrof BJ, Gea J, Comtois N, Grassino AE. Diaphragm muscle fiber injury after inspiratory resistive breathing. Am J Respir Crit Care Med 1997, 155:1110-1116.
74. Verheul AJ, Hafmans T, Croes HJ, Dekhuijzen PNR. Cytoskeletal accumulations in the diaphragm muscle of patients with COPD. Am J Respir Crit Care Med 2006, 169:A245.
75. Wijnhoven JH, Hafmans T, Dekhuijzen PN. Distribution of costameric proteins in the diaphragm of patients with chronic obstructive pulmonary disease. Respiration 2006, 73:529-537. 10.1159/000091270, 16449803.
76. Verheul AJ, Oosterhof A, Croes HJ, Dekhuijzen PN. Satellite cell characteristics in diaphragm muscle from COPD patients. Am J Respir Crit Care Med 2006, 165:A308.
77. Verheul AJ, Croes HJ, Ginsel LA, Dekhuijzen PN. Tendency towards decreased expression of neonatal myosin heavy chains in diaphragm muscle fibers from patients with COPD compared to healthy subjects. Am J Respir Crit Care Med 2006, 163:A146.
78. Degens H, Swisher AK, Heijdra YF, Siu PM, Dekhuijzen PN, Alway SE. Apoptosis and Id2 expression in diaphragm and soleus muscle from the emphysematous hamster. Am J Physiol Regul Integr Comp Physiol 2007, 293:R135-R144.
79. Kolbeck RC, She ZW, Callahan LA, Nosek TM. Increased superoxide production during fatigue in the perfused rat diaphragm. Am J Respir Crit Care Med 1997, 156:140-145.
80. Posterino GS, Lamb GD. Effects of reducing agents and oxidants on excitation-contraction coupling in skeletal muscle fibres of rat and toad. J Physiol 1996, 496 ( Pt 3):809-825. 1160866, 8930846.
81. Whittom F, Jobin J, Simard PM, Leblanc P, Simard C, Bernard S, Belleau R, Maltais F. Histochemical and morphological characteristics of the vastus lateralis muscle in patients with chronic obstructive pulmonary disease. Med Sci Sports Exerc 1998, 30:1467-1474. 10.1097/00005768-199810000-00001, 9789845.
82. Satta A, Migliori GB, Spanevello A, Neri M, Bottinelli R, Canepari M, Pellegrino MA, Reggiani C. Fibre types in skeletal muscles of chronic obstructive pulmonary disease patients related to respiratory function and exercise tolerance. Eur Respir J 1997, 10:2853-2860. 10.1183/09031936.97.10122853, 9493673.
83. Jakobsson P, Jorfeldt L, Brundin A. Skeletal muscle metabolites and fibre types in patients with advanced chronic obstructive pulmonary disease (COPD), with and without chronic respiratory failure. Eur Respir J 1990, 3:192-196.
84. Maltais F, Sullivan MJ, Leblanc P, Duscha BD, Schachat FH, Simard C, Blank JM, Jobin J. Altered expression of myosin heavy chain in the vastus lateralis muscle in patients with COPD. Eur Respir J 1999, 13:850-854. 10.1034/j.1399-3003.1999.13d26.x, 10362052.
85. Maltais F, Leblanc P, Whittom F, Simard C, Marquis K, Belanger M, Breton MJ, Jobin J. Oxidative enzyme activities of the vastus lateralis muscle and the functional status in patients with COPD. Thorax 2000, 55:848-853. 10.1136/thorax.55.10.848, 10992537.
86. Gosker HR, van MH, van Dijk PJ, Engelen MP, van, Wouters EF, Schols AM. Skeletal muscle fibre-type shifting and metabolic profile in patients with chronic obstructive pulmonary disease. Eur Respir J 2002, 19:617-625. 10.1183/09031936.02.00762001, 11998989.
87. Agusti AG, Sauleda J, Miralles C, Gomez C, Togores B, Sala E, Batle S, Busquets X. Skeletal muscle apoptosis and weight loss in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2002, 166:485-489. 10.1164/rccm.2108013, 12186825.
88. Gosker HR, Engelen MP, van Mameren H, van Dijk PJ, van der Vusse GJ, Wouters EF, Schols AM. Muscle fiber type IIX atrophy is involved in the loss of fat-free mass in chronic obstructive pulmonary disease. Am J Clin Nutr 2002, 76:113-119.
89. Allaire J, Maltais F, Leblanc P, Simard PM, Whittom F, Doyon JF, Simard C, Jobin J. Lipofuscin accumulation in the vastus lateralis muscle in patients with chronic obstructive pulmonary disease. Muscle Nerve 2002, 25:383-389. 10.1002/mus.10039, 11870715.
90. Gosker HR, Bast A, Haenen GR, Fischer MA, van, Wouters EF, Schols AM. Altered antioxidant status in peripheral skeletal muscle of patients with COPD. Respir Med 2005, 99:118-125. 10.1016/j.rmed.2004.05.018, 15672860.
91. Engelen MP, Schols AM, Does JD, Deutz NE, Wouters EF. Altered glutamate metabolism is associated with reduced muscle glutathione levels in patients with emphysema. Am J Respir Crit Care Med 2000, 161:98-103.
92. Barreiro E, Gea J, Corominas JM, Hussain SN. Nitric oxide synthases and protein oxidation in the quadriceps femoris of patients with chronic obstructive pulmonary disease. Am J Respir Cell Mol Biol 2003, 29:771-778. 10.1165/rcmb.2003-0138OC, 12816735.
93. Montes de OM, Torres SH, De SJ, Mata A, Hernandez N, Talamo C. Skeletal muscle inflammation and nitric oxide in patients with COPD. Eur Respir J 2005, 26:390-397. 10.1183/09031936.05.00107404, 16135718.
94. Agusti A, Morla M, Sauleda J, Saus C, Busquets X. NF-kappaB activation and iNOS upregulation in skeletal muscle of patients with COPD and low body weight. Thorax 2004, 59:483-487. 10.1136/thx.2003.017640, 15170030.
95. Orozco-Levi M. Structure and function of the respiratory muscles in patients with COPD: impairment or adaptation?. Eur Respir J Suppl 2003, 46:41s-51s.
96. Polkey MI, Kyroussis D, Keilty SE, Hamnegard CH, Mills GH, Green M, Moxham J. Exhaustive treadmill exercise does not reduce twitch transdiaphragmatic pressure in patients with COPD. Am J Respir Crit Care Med 1995, 152:959-964.
97. Chamberlain JS. Cachexia in cancer--zeroing in on myosin. N Engl J Med 2004, 351:2124-2125. 10.1056/NEJMcibr042889, 15537911.
98. Acharyya S, Ladner KJ, Nelsen LL, Damrauer J, Reiser PJ, Swoap S, Guttridge DC. Cancer cachexia is regulated by selective targeting of skeletal muscle gene products. J Clin Invest 2004, 114:370-378. 484974, 15286803, 10.1172/JCI200420174.
99. Horowits R, Podolsky RJ. The positional stability of thick filaments in activated skeletal muscle depends on sarcomere length: evidence for the role of titin filaments. J Cell Biol 1987, 105:2217-2223. 10.1083/jcb.105.5.2217, 3680378.
100. Lange S, Xiang F, Yakovenko A, Vihola A, Hackman P, Rostkova E, Kristensen J, Brandmeier B, Franzen G, Hedberg B, Gunnarsson LG, Hughes SM, Marchand S, Sejersen T, Richard I, Edstrom L, Ehler E, Udd B, Gautel M. The kinase domain of titin controls muscle gene expression and protein turnover. Science 2005, 308:1599-1603. 10.1126/science.1110463, 15802564.
101. Gomes-Marcondes MC, Tisdale MJ. Induction of protein catabolism and the ubiquitin-proteasome pathway by mild oxidative stress. Cancer Lett 2002, 180:69-74. 10.1016/S0304-3835(02)00006-X, 11911972.
102. Halliwell B, Whiteman M. Measuring reactive species and oxidative damage in vivo and in cell culture: how should you do it and what do the results mean?. Br J Pharmacol 2004, 142:231-255. 1574951, 15155533, 10.1038/sj.bjp.0705776.
103. Travaline JM, Sudarshan S, Roy BG, Cordova F, Leyenson V, Criner GJ. Effect of N-acetylcysteine on human diaphragm strength and fatigability. Am J Respir Crit Care Med 1997, 156:1567-1571.
104. Laghi F, Jubran A, Topeli A, Fahey PJ, Garrity ER, Arcidi JM, de Pinto DJ, Edwards LC, Tobin MJ. Effect of lung volume reduction surgery on neuromechanical coupling of the diaphragm. Am J Respir Crit Care Med 1998, 157:475-483.
105. Reid MB, Lannergren J, Westerblad H. Respiratory and Limb Muscle Weakness Induced by Tumor Necrosis Factor- alpha: Involvement of Muscle Myofilaments. Am J Respir Crit Care Med 2002, 166:479-484. 10.1164/rccm.2202005, 12186824.
106. Li YP, Chen Y, Li AS, Reid MB. Hydrogen peroxide stimulates ubiquitin-conjugating activity and expression of genes for specific E2 and E3 proteins in skeletal muscle myotubes. Am J Physiol Cell Physiol 2003, 285:C806-C812.
107. Li YP, Chen Y, John J, Moylan J, Jin B, Mann DL, Reid MB. TNF-alpha acts via p38 MAPK to stimulate expression of the ubiquitin ligase atrogin1/MAFbx in skeletal muscle. FASEB J 2005, 19:362-370. 10.1096/fj.04-2364com, 15746179.
108. Langen RC, Van Der Velden JL, Schols AM, Kelders MC, Wouters EF, Janssen-Heininger YM. Tumor necrosis factor-alpha inhibits myogenic differentiation through MyoD protein destabilization. FASEB J 2004, 18:227-237. 10.1096/fj.03-0251com, 14769817.
109. Godoy I, Campana AO, Geraldo RR, Padovani CR, Paiva SA. Cytokines and dietary energy restriction in stable chronic obstructive pulmonary disease patients. Eur Respir J 2003, 22:920-925.
110. Di Francia M, Barbier D, Mege JL, Orehek J. Tumor necrosis factor-alpha levels and weight loss in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1994, 150:1453-1455.
111. Broekhuizen R, Wouters EF, Creutzberg EC, Schols AM. Raised CRP levels mark metabolic and functional impairment in advanced COPD. Thorax 2006, 61:17-22. 10.1136/thx.2005.041996, 16055618.
112. van Helvoort HA, Heijdra YF, Thijs HM, Vina J, Wanten GJ, Dekhuijzen PNR. Exercise-induced systemic effects in muscle-wasted patients with COPD. Med Sci Sports Exerc 2006, 38:1543-1552. 10.1249/01.mss.0000228331.13123.53, 16960513.
113. Vernooy JH, Kucukaycan M, Jacobs JA, Chavannes NH, Buurman WA, Dentener MA, Wouters EF. Local and systemic inflammation in patients with chronic obstructive pulmonary disease: soluble tumor necrosis factor receptors are increased in sputum. Am J Respir Crit Care Med 2002, 166:1218-1224. 10.1164/rccm.2202023, 12403691.
114. Vassilakopoulos T, Divangahi M, Rallis G, Kishta O, Petrof B, Comtois A, Hussain SN. Differential cytokine gene expression in the diaphragm in response to strenuous resistive breathing. Am J Respir Crit Care Med 2004, 170:154-161. 10.1164/rccm.200308-1071OC, 15117743.
115. Vassilakopoulos T, Roussos C, Zakynthinos S. Is loaded breathing an inflammatory stimulus?. Curr Opin Crit Care 2005, 11:1-9. 10.1097/00075198-200502000-00002, 15659939.